Capital Formation Series, Part 4
Opportunity vs. Vulnerability in New Fundraising Initiatives
By Trista Morrison
Monday, December 5, 2011
It seems increasingly likely that at least some of Congress's capital formation bills will soon become law, and that those laws will bode well for private biotechs by creating new fundraising pathways.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.